CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Total revenue	$ 1,141	$ 485	$ 2,155	$ 928
Operating expenses
Research and development	8,902	14,574	15,728	24,746
General and administrative	7,688	9,451	14,092	17,757
Total operating expenses	16,590	24,025	29,820	42,503
Loss from operations	(15,449)	(23,540)	(27,665)	(41,575)
Other income (expense), net	169	475	461	1,184
Net loss	(15,280)	(23,065)	(27,204)	(40,391)
Other comprehensive income (loss)
Foreign currency translation adjustment	3	(2)	8	(3)
Unrealized gain (loss) on marketable securities	0	(1)	0	(1)
Comprehensive loss	(15,277)	(23,068)	(27,196)	(40,395)
Net loss — basic and diluted	(15,280)	(23,065)	(27,204)	(40,391)
Redeemed Series B convertible preferred stock	4,988	0	4,988	0
Net loss available to common shareholders— basic	(10,292)	(23,065)	(22,216)	(40,391)
Net loss available to common shareholders— diluted	$ (10,292)	$ (23,065)	$ (22,216)	$ (40,391)
Shares used in calculating net loss per common share - basic (in shares)	257,353,857	238,311,498	257,293,247	231,952,888
Shares used in calculating net loss per common share - diluted (in shares)	257,353,857	238,311,498	257,293,247	231,952,888
Net loss per share available to common shareholders — basic (in USD per share)	$ (0.04)	$ (0.10)	$ (0.09)	$ (0.17)
Net loss per share available to common shareholders — diluted (in USD per share)	$ (0.04)	$ (0.10)	$ (0.09)	$ (0.17)
Collaborative Arrangements
Total revenue	$ 1,141	$ 485	$ 2,155	$ 928
Operating expenses
Research and development			$ 400	$ 2,300